

PRESS
RELEASE

New generation of single-use airway device gets market clearance for USA

Ambu has obtained FDA-clearance for its second generation single-use double-lumen tube – VivaSight 2 DLT – an innovative technological solution for single-lung ventilation procedures.

Today, Ambu announces the US regulatory clearance of the company's latest innovation, Ambu® VivaSight™ 2 DLT, an airway tube with built-in camera. The VivaSight 2 DLT has received 510(k) clearance and will be commercially launched during Q3 of Ambu's financial year 2020/21.

"VivaSight 2 DLT is an advanced single-use device designed to give healthcare professionals a safe and cost-effective way to perform single-lung ventilation procedures. We have developed VivaSight 2 DLT in close collaboration with leading anaesthesiologists, and we are proud to bring new innovation to clinicians. This is a further step towards the most advanced offering in single-use pulmonology," says Juan Jose Gonzalez, CEO of Ambu.

VivaSight 2 DLT provides clinicians with continuous visual monitoring of tube positioning throughout the entire surgical procedure via a live video feed. This means that the clinician can immediately detect and correct the positioning of the tube if it becomes displaced during surgery.

Ambu's single-use pulmonology portfolio will be further expanded this year with a fifth-generation bronchoscope and next year with an upgraded video laryngoscope as part of Ambu's strategy of rapid innovation.

Acquisition and development

Ambu acquired the first generation of VivaSight in 2016 and began the technical integration with Ambu's bronchoscopy solution making VivaSight compatible with Ambu's aView™ processor. The new generation, VivaSight 2 DLT, features several improvements including higher image resolution, integration with the latest monitor technology and the possibility of simultaneous view in combination with a bronchoscope.

Ambu is the leading developer, manufacturer and supplier of innovative single-use endoscopes with the aim of increasing patient safety and improving healthcare workflows.

Contacts

Investors

Nicolai Thomsen, Director, Investor Relations & Strategic Financial Planning, nith@ambu.com / +45 2620 8047

Media

Mikkel Trier Wagner, Director, Corporate Communications, mtw@ambu.com / +45 4191 0830

Ambu A/S

Baltorpbakken 13, DK-2750 Ballerup, Denmark, Tel.: +45 7225 2000, CVR no.: 63 64 49 19, www.ambu.com

About Ambu

Ambu has been bringing the solutions of the future to life since 1937. Today, millions of patients and healthcare professionals worldwide depend on the efficiency, safety and performance of our single-use endoscopy, anaesthesia, and patient monitoring & diagnostics solutions. The manifestations of our efforts have ranged from early innovations like the Ambu® Bag™ resuscitator and the Ambu® BlueSensor™ electrodes to our newest landmark solutions like the Ambu® aScope™ – the world's first single-use flexible endoscope. Moreover, we continuously look to the future with a commitment to deliver innovative quality products that have a positive impact on the work of doctors, nurses and paramedics. Headquartered near Copenhagen in Denmark, Ambu employs approximately 4,500 people in Europe, North America and the Asia Pacific. For more information, please visit ambu.com.